Going at a distance – insights into how cancer cells spread

Most tumors involve a heterogenous mixture of cells. Genetic mutations found directly in some of these cells are known to help with the spread and progression of cancer. However, oncologists often find that when tumors metastasize to distant organs, they retain this heterogenous nature – something called “polyclonal metastasis”. The way in which non-metastatic cells go with the metastatic metastatic cells is ambiguous. Now, Masanobu Oshima and his research team have used mouse models to explain how non-metastatic cells begin their long journey.

The team has developed several cancerous mutants of mice and analyzed them to determine which cancer cells are most likely to spread and which are not. Cells with four mutations, colloquially known as AKTP, have been found to be the most lethal. When these cells were transplanted into mouse spleens, they migrated to and formed colonies in the mice within 3 days. In contrast, cells with two mutations, AK and AP, could not exceed this speed. To replicate polyclonal metastasis, AP cells were then synthesized by AKTP cells, and voila, in fact, both cell types moved into the ovaries. Instead, when AP cells were introduced into the bloodstream (without prior exposure to the AKTP cells) they could not metastasize. Some processes appeared to be at play when the cells were grouped together.

Next, AKTP cells inside the liver tumors were killed to see how closely that affected the AP cells. The AP cells continued to thrive and grew into larger tumors suggesting that they no longer needed the AKTP cells. Thus, at some point of the journey from the spleen to the liver the AP cells turned dangerous. To mark this point, the researchers traced back the sequence of events. Within a day after transplantation, AKTP accumulations were detected in the sinusoid vessel, a major blood vessel that supplied the liver. Within 14 days, this group had evolved into a major fibrotic phenomenon. The same mass was observed with a combination of AP and AKTP cells, but not exclusively with AP cells. Moreover, within this mass were AKTP cells activating hepatic stellate cells (HSCs). HSCn is responsible for breaking down liver fatigue. Activated HSCn then establishes the perfect environment for AP cells to expand indefinitely. The portalization of the AP cells within the fibrotic environment was therefore a key step.

“These results show that non-metastatic cells can metastasize through the polyclonal metastasis mechanism using the fibrotic niche induced by malignant cells,” the researchers concluded. targeting this fibrotic area to monitor the spread of hard tumors is promising.

###

Polyclonal metastasis: Solid tumors such as breast and colorectal cancers are known to spread spontaneously. These tumor cells break down from where they came from and migrate through the bloodstream to distant organs to form a store. These metastatic tumors are often found to be genetically diverse in nature. However, the role of cancer mutations in the metastasis of metastatic tumors is not yet clear. Old theories have suggested that genetic modification is the only major way to convert cells to metastases. However, the review shown here shows that other devices are also in play.

Hepatic stellate cells (HSCs) and the fibrotic niche: HSCs are specific cells of the liver responsible for scarring and wound healing devices when activated. When activated, (following events such as liver damage) HSCns begin to reduce and stimulate fibrotic tension within the liver. Thus, their activation by AKTP cells resulted in the development of the fibrotic space, an environment that is particularly favorable for tumor proliferation.